Context-dependent functions of insulin, IGF, and GLP signaling in inflammatory bowel disease: linking metabolism, immunity, and intestinal homeostasis
7 affiliations
- 1Children’s Research Institute, University of North Carolina at Chapel Hill
- 2Department of Pediatrics, University of North Carolina at Chapel Hill
- 3Department of Rheumatology and Inflammation Research, University of Gothenburg
- 4Dietrich School of Arts & Sciences, University of Pittsburgh
- 5Laboratory of Animal Food Function, School of Agricultural Science, Tohoku University
- 6Department of Pediatric Surgery, School of Medicine Juntendo University
- 7Faculty of Medical Sciences, Newcastle University
Abstract
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract characterized by dysregulated immune responses, impaired epithelial barrier function, and alterations in the gut microbiota. Although considerable progress has been made in understanding the immunopathogenesis of IBD, increasing evidence indicates that metabolic signaling pathways are integral regulators of intestinal inflammation, tissue repair, and disease progression. Among these, insulin, insulin-like growth factors (IGFs), and glucagon-like peptides (GLPs) constitute an interconnected immunometabolic network that links nutrient sensing, energy metabolism, epithelial regeneration, and immune homeostasis. Insulin signaling plays context-dependent roles in IBD by regulating glucose metabolism, epithelial repair, inflammatory responses, and interactions with the gut microbiota and bile acid metabolism. While insulin promotes mucosal healing and barrier restoration in intestinal epithelial cells, excessive activation of insulin signaling in immune cells may exacerbate chronic inflammation through epigenetic and cytokine-mediated mechanisms. The IGF axis is also profoundly altered during active IBD, with systemic suppression of IGF-1 and IGFBP-3 accompanying disease activity, whereas local IGF signaling promotes epithelial regeneration, wound healing, and immune regulation. In addition, IGF-binding proteins (IGFBPs) function as active modulators of inflammation, fibrosis, and colitis-associated colorectal cancer in an isoform-specific manner. GLP signaling further integrates metabolism with intestinal immunity; GLP-1 receptor agonists exhibit anti-inflammatory, metabolic, and microbiota-modulating effects, whereas GLP-2 primarily enhances epithelial proliferation, barrier integrity, and mucosal repair. Emerging preclinical and observational clinical studies suggest that GLP-based therapies may improve disease outcomes, although prospective randomized trials are still required. This review summarizes current knowledge regarding the biological functions and molecular mechanisms of insulin, IGFs, IGFBPs, and GLPs in IBD, highlighting their coordinated roles in regulating metabolism, immunity, epithelial homeostasis, and tissue remodeling. A better understanding of these interconnected signaling pathways may facilitate the development of novel immunometabolic therapeutic strategies aimed at promoting mucosal healing, limiting chronic inflammation, and improving long-term outcomes in patients with IBD.
Related
- Cross-regulatory sRNA networks shape adaptive stress responses in Staphylococcus aureus: RsaC and RsaOI regulate galactose metabolism and cell wall homeostasis
- Maternal gut microbiota, tryptophan metabolism and immune homeostasis: Implications for the prevention of adverse pregnancy complications
- Gut Microbiota-Mucosal Immune Interactions Underlying Intestinal Homeostasis in Weaned Piglets.
- Epithelial CD74 regulates intestinal barrier homeostasis
- KARAP deficiency alleviates intestinal mucosal barrier dysfunction by regulating mitochondrial homeostasis in macrophages.
BibTeX
@article{abuhussein2026contextdependent,
title = {{Context-dependent functions of insulin, IGF, and GLP signaling in inflammatory bowel disease: linking metabolism, immunity, and intestinal homeostasis}},
author = {Ezzuddin Abuhussein and Yukihiro Yamaguchi and Dhirendra K. Singh and Chiara Elena Orahovats and Keita Nishiyama and Koichi Tsuboi and Lei Huang},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1970634},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1970634/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Context-dependent functions of insulin, IGF, and GLP signaling in inflammatory bowel disease: linking metabolism, immunity, and intestinal homeostasis
AU - Ezzuddin Abuhussein
AU - Yukihiro Yamaguchi
AU - Dhirendra K. Singh
AU - Chiara Elena Orahovats
AU - Keita Nishiyama
AU - Koichi Tsuboi
AU - Lei Huang
PY - 2026
DA - 2026/10/21
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1970634
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1970634/full
AB - Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract characterized by dysregulated immune responses, impaired epithelial barrier function, and alterations in the gut microbiota. Although considerable progress has been made in understanding the immunopathogenesis of IBD, increasing evidence indicates that metabolic signaling pathways are integral regulators of intestinal inflammation, tissue repair, and disease progression. Among these, insulin, insulin-like growth factors (IGFs), and glucagon-like peptides (GLPs) constitute an interconnected immunometabolic network that links nutrient sensing, energy metabolism, epithelial regeneration, and immune homeostasis. Insulin signaling plays context-dependent roles in IBD by regulating glucose metabolism, epithelial repair, inflammatory responses, and interactions with the gut microbiota and bile acid metabolism. While insulin promotes mucosal healing and barrier restoration in intestinal epithelial cells, excessive activation of insulin signaling in immune cells may exacerbate chronic inflammation through epigenetic and cytokine-mediated mechanisms. The IGF axis is also profoundly altered during active IBD, with systemic suppression of IGF-1 and IGFBP-3 accompanying disease activity, whereas local IGF signaling promotes epithelial regeneration, wound healing, and immune regulation. In addition, IGF-binding proteins (IGFBPs) function as active modulators of inflammation, fibrosis, and colitis-associated colorectal cancer in an isoform-specific manner. GLP signaling further integrates metabolism with intestinal immunity; GLP-1 receptor agonists exhibit anti-inflammatory, metabolic, and microbiota-modulating effects, whereas GLP-2 primarily enhances epithelial proliferation, barrier integrity, and mucosal repair. Emerging preclinical and observational clinical studies suggest that GLP-based therapies may improve disease outcomes, although prospective randomized trials are still required. This review summarizes current knowledge regarding the biological functions and molecular mechanisms of insulin, IGFs, IGFBPs, and GLPs in IBD, highlighting their coordinated roles in regulating metabolism, immunity, epithelial homeostasis, and tissue remodeling. A better understanding of these interconnected signaling pathways may facilitate the development of novel immunometabolic therapeutic strategies aimed at promoting mucosal healing, limiting chronic inflammation, and improving long-term outcomes in patients with IBD.
SN - 1664-3224
ER -